ArticleAsian Pacific journal of cancer prevention : APJCP2025
Real-World Effectiveness and Safety of Ribociclib Plus Aromatase Inhibitors in Patients with HR+/HER2- Metastatic Breast Cancer: A Multicenter Experience from Vietnam.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough CDK4/6 inhibitors have demonstrated efficacy globally, real-world data from Vietnam are limited, primarily due to financial constraints. This study aimed to evaluate the effectiveness and toxicity of ribociclib combined with aromatase inhibitors (AIs) in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (mBC) in a real-world study setting.
methodsThis retrospective study included patients with de novo or recurrent hormone receptor-positive, HER2-negative metastatic breast cancer who were treated at two cancer centers between May 2021 and April 2024. The primary endpoint was progression-free survival (PFS), which was analyzed via the Kaplan-Meier method, with comparisons via the log-rank test and Cox regression. The secondary endpoints were the objective response rate (ORR) per RECIST 1.1, overall survival (OS), and adverse events graded by CTCAE 5.0.
resultsA total of 92 female patients were eligible for the study. The mean age was 53.8±12.1 years. Among the patients, 69.6% received first line of treatment, and 30.4% were in subsequent lines. The median PFS (mPFS) was 19.1 months (95% CI: 14.3-26.2) in all patients, with a median follow-up time of 28.2 months. The rates of complete response, partial response, stable disease, and progressive disease were 2.2%, 55.4%, 37.0%, and 5.4%, respectively. PFS was lower in patients with liver metastasis (11.7 months vs. 21.8 months, p=0.030). With a median follow-up time of 27.9 months, the median OS was not reached, and the 3-year OS rate was 61.4%. Common adverse events (any grade/grade ≥3) included neutropenia (80.4/47.8%), elevated alanine transaminase (33.7%/3.3%), elevated aspartate transaminase (31.5%/3.3%), nausea (18.5%/0%), and thrombocytopenia (13.0%/0%). No treatment-related deaths were observed.
conclusionRibociclib combined with aromatase inhibitors demonstrated favorable real-world effectiveness and manageable safety profiles in Vietnamese patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real-world setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.